Breakout, retest, potential triple bottom Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.
I actually trade this for 15-20% gains on deep supply zones. Last time I got in was .51 so not bad if you understand where to buy in. I like the swings in this stock and has some volume. Bullish weekly at least to start off next week. Might fail right away with the resistance and the highs. Just need a solid open above .73. Still not banking on that. Just wanted...
This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019). Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) - ir.novavax.com Vaccine in development for SARS-CoV-2 (2019): seekingalpha.com Is this a good investment? If the vaccination is successful and/or coronavirus outbreak...
the beta is high with this one
The chart depicts a classic cup and handle formation. Place a stop buy order slightly above the upper trend line of the handle. There is a risk of missing the trade if the price continues to advance and does not pull back. TEVA is still undervalued compared to fair value - they reported positive drug trial data in Japan, and had a nice breakout this week. gl!
Ignore the day to day... focus on the end game. It's a perfect setup.
We have a triple rejection of the sub 8.60 price range on the weekly candles, setup doesn't get much better than that. Consolidation has taken longer than expected but what else is new haha.
After the massive price drop at the end of July, Pfizer is pivoting its strategy selling Upjohn Unit to a new joint venture with Mylan and focusing on the new BioPharma business (mainly focusing on Ibrance, Xtandi, Inlyta, etc.). The new strategy provides Pfizer with a wide economic moat. I think the market currently undervalues the stock. The current price is...
I would be cautious of the handle getting any longer. Other than that it looks to be at the end of consolidation.
If you like this idea, don't forget to hit the Like Button! Alexion business depends on patent-protected therapies in ultrarare and rare diseases of high unmet medical needs. While competitors are entering the market with biosimilars, Alexion still maintains an essential share of the market. My long term view is bullish. However, from a technical point of view,...
I think we will see a sharp move this month. From reading the chart alone I am wagering it's going to be a bullish move... even though the fundamentals of the company are up for debate.
Good spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud). I was waiting for today's opening to confirm a bullish position. Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89). Disclosure: My ideas contain statements and projections based on...
Abnormal volume breakout with next resistance at .095
BIOS looks to potentially be in a bullish cup and handle pattern that could potential send the stock to $6.
What are the thoughts here? News? -NOPE...pure momentum today? Biggest volume it's had since the big drop day so what can explain this move? "Intec Pharma Ltd. is a biotechnology company that creates drugs using its Accordion Pill technology. This technology is designed to improve the safety of drugs when taken orally. The company currently has 5 treatments in...
Morningstar weekly highlights set Biomarin Pharmaceuticals with an amazing $119 fair price value ( 50% above current price). Rating: 4 stars Uncertainty rating: Medium Moat: Narrow